Extended Data Table 2.
Adverse events according to system organ class*
| Cloxacillin plus Fosfomycin (n = 104) | Cloxacillin alone (n = 110) | |
|---|---|---|
| Blood and lymphatic system disorders | 1 | 0 |
| Cardiac disorders | 9 | 7 |
| Gastrointestinal disorders | 7 | 6 |
| General disorders and administration site conditions | 4 | 7 |
| Hepatobiliary disorders | 1 | 0 |
| Infections and infestations | 13 | 20 |
| Injury, poisoning and procedural complications | 3 | 0 |
| Investigations | 1 | 0 |
| Metabolism and nutrition disorders | 25 | 20 |
| Musculoskeletal and connective tissue disorders | 0 | 2 |
| Neoplasms benign, malignant and unspecified (including cysts and polyps) | 5 | 4 |
| Nervous system disorders | 1 | 1 |
| Product issues | 1 | 0 |
| Renal and urinary disorders | 2 | 3 |
| Respiratory, thoracic and mediastinal disorders | 2 | 6 |
| Surgical and medical procedures | 4 | 1 |
| Vascular disorders | 3 | 4 |
*Adverse events are reported based on Conventional International Conference on Harmonization definitions. Patients could have more than one adverse event.